Transcription of the human polyomavirus JC virus (JCV) genome is regulated by cellular proteins and the large tumour (T) antigen. Earlier studies led to the identification of nuclear factor-1 (NF-1)-binding sites in the JCV enhancer by DNase I protection assays of extracts from retinoic acid (RA)-differentiated P19 embryonal carcinoma (EC) cells. In this study, a cDNA clone that encodes a protein capable of binding to the JCV NF-1 sites was isolated from an RA-differentiated EC cell cDNA library. Sequence analysis revealed that the cDNA isolated was identical to the previously described Bcl-2-interacting protein BAG-1 (Bcl-2-associated athano gene-1). Results from RNA studies indicated that BAG-1 is expressed in several cell types. Co-transfection of a recombinant BAG-1 expression plasmid with JCV promoters indicated that BAG-1 stimulates transcription of the JCV E promoter and to a lesser extent the JCV L promoter. Mutations in the NF-1 sites in the JCV E promoter eliminated the activation by BAG-1. Thus, BAG-1 is a novel transcription factor that may play a role in JCV expression.
Introduction
The human polyomavirus JC virus (JCV) is the aetiological agent of progressive multifocal leukoencephalopathy (PML) (reviewed in Major et al., 1992 ; Weber & Major, 1997) . This virus is closely related to two other polyomaviruses, the simian virus 40 (SV40) and BK viruses, which share more than 70 % identity in their protein-coding regions (Frisque et al., 1984) . However, compared with BK virus and SV40, JCV has a narrower host range and tissue tropism. The greatest divergence between JCV and the other polyomaviruses is in the virus control region, which contains promoters for early and late gene transcription and is organized as two 98 bp direct repeats. Several lines of evidence gained in vitro and in vivo, including in vitro transcription from the virus promoters in neuronal and non-neuronal cell extracts (Ahmed et al., 1990 ; Kumar et al., 1993) and transient transfection of glial and nonglial cells with CAT reporter plasmids (reviewed in Raj & Khalili, 1995) , indicated that the JCV early and late promoters are more active in cells derived from the central nervous system (reviewed in Raj & Khalili, 1995) . Thus, these data suggest that the tissue tropism of JCV, at least to a large extent, rests on tissue-specific expression of the virus promoters. Previous studies have indicated that the cell-specific activation of the JCV promoter requires its association with multiple cellular transcription factors present in neuronal cells (reviewed in Raj & Khalili, 1995) .
Embryonal carcinoma (EC) cells are pluripotent in nature and can be differentiated with chemicals into several different cell lineages. For example, retinoic acid (RA) and DMSO induce neuron-and skeletal muscle cell-like morphologies, respectively. Thus, the EC cell system serves as a model system for studying neuron-specific gene expression. Previous studies from our laboratory have shown that the JCV promoter is active only in RA-differentiated and not in undifferentiated or DMSO-differentiated EC cells (Nakshatri et al., 1990 ; Kumar et al., 1993) . Nuclear extracts prepared from RA-differentiated cells protect nuclear factor-1 (NF-1)-like sequences in the JCV promoter (Nakshatri et al., 1990 ; Kumar et al., 1993) and disruption of these sites reduces the activity of the JCV promoter (Kumar et al., 1993) . Furthermore, a novel factor 0001-6618 # 2000 SGM DFB present in RA-differentiated EC cells seems to interact with these sites, as judged by the results of band-shift and UV crosslinking assays (Kumar, 1994) . However, the identity and nature of this protein remain unknown. Cloning and characterization of such factors may shed more light on neuron-specific expression of human JCV.
BAG-1 (Bcl-2-associated athano gene-1) is a novel Bcl-2-interacting protein that was first identified as a multifunctional molecule that binds to the anti-apoptotic protein Bcl-2 and promotes cell survival (Takayama et al., 1995) . Since its discovery, BAG-1 has been shown to form complexes with several other proteins, including tyrosine kinase growth-factor receptors such as hepatocyte-and platelet-derived growth factors (Bardelli et al., 1996) , the serine\threonine protein kinase Raf-1 (Wang et al., 1996 ; reviewed in Wang & Reed, 1998) and the retinoic acid receptor (Liu et al., 1998) . Alternative translation of BAG-1 generates a series of proteins with variable lengths (Packham et al., 1997) . Longer forms of BAG-1, with unique amino-terminal domains, have also been reported to form complexes with steroid-hormone receptors (Packham et al., 1997 ; . Binding of BAG-1 to these molecules modulates their activity. The mechanism by which BAG-1 influences the activities of such diverse proteins can perhaps be attributed to its ability to bind heat-shock proteins directly, which in turn interact with multiple target proteins in cells. BAG-1 contains an amino-terminal region with similarity to ubiquitin and a central region that binds Bcl-2 (Takayama et al., 1995) . Its carboxy terminus is required for formation of complexes with Raf-1 and growth factor receptors.
It is well established that the expression of JCV early and late genes, encoding the tumour (T) antigen and capsid proteins, respectively, determines the narrow host range and specificity of this virus. Studies from our lab and other laboratories have demonstrated that the JC promoter\enhancer functions more efficiently in neuronal cells than in nonneuronal cells. The studies presented here attempt to identify the proteins that bind the JCV promoter\enhancer region. Here, we report the cloning of a novel protein by Southwestern screening of a P19 RA-differentiated cDNA library with a JCV NF-1 probe. Interestingly, this protein is identical to a Bcl-2-interacting protein, BAG-1. Furthermore, this protein is able to bind the NF-1 sequence and transactivate JCV promoters.
Methods
Cells, plasmids and transfection procedures. P19 EC, U87 MG human glioblastoma and HeLa cells were maintained in Dulbecco's modified Eagle's medium. P19 cells were differentiated with 1 % DMSO into skeletal or cardiac muscle cells or differentiated with 300 nM all trans-retinoic acid (Sigma) into neuron-like cells as described previously (Nakshatri et al., 1990) . Plasmids pCMV, pBluescript KS(j) and pUC19 were purchased from Invitrogen, Stratagene and New England Biolabs, respectively. pJCV E , JCV L , RII E , II "! (bearing mutations in two NF-1 sites present within the two 98 bp repeats) and DM "! (bearing mutations in all three NF-1 sites), CAT reporter plasmids and pRSV-β-Gal were described by Nakshatri et al. (1990) and Kumar et al. (1993) . BK E CAT (BK virus early promoter linked to the CAT gene) was described by Nakshatri et al. (1991) . Cells were transfected with the amounts of plasmids indicated by the calcium phosphate method as described by Kumar et al. (1993) .
Oligonucleotides. The sequences of wild-type (WT) and mutant (mt) JCV NF-1 oligonucleotides used are : WT NF-1, 5h TGGCTG-CCAGCCAA 3h ; and mt NF-1, 5h gtaCTGCCAGaCcAGCA 3h (see Kumar et al., 1993) . Lower-case letters indicate mutated bases.
Construction and screening of the cDNA library. A λgt22A cDNA library from mRNA of P19 RA-differentiated cells was made by using a kit from GIBCO-BRL according to the manufacturer's instructions. Screening of the cDNA expression library was performed by the Southwestern blot method of Vinson et al. (1988) . Freshly prepared E. coli Y1090R − bacteria were infected with recombinant phage from the P19 RA λgt22A library at " 5i10% p.f.u. per 150 mm plate. The infection was performed by incubating at 37 mC for 30 min. Next, 7n5 ml 0n7 % top agarose was mixed with the bacteria and the mixture was overlaid onto 1n5 % T-Tyn (tryptone, yeast extract and NaCl) agar plates. After incubation at 42 mC for 4 h, IPTG-impregnated nitrocellulose filters were overlaid onto the plates and the plates were incubated for additional 6 h at 37 mC. The filters were then removed from the plates, air-dried and immersed in binding buffer (6 M guanidine-HCl ; 25 mM HEPES, pH 7n9; 3 mM MgCl # ; 4 mM KCl and 1 mM DTT) for 5 min at 4 mC with gentle agitation. The binding buffer was then diluted with an equal volume of the same buffer but containing variable amounts of guanidine-HCl and the filters were incubated in these diluted buffers for 5 min each. The filters were then washed with binding buffer without guanidine-HCl. The filters were then blocked by incubating in binding buffer containing 5 % non-fat dried milk powder for 30 min at 4 mC. After rinsing in binding buffer containing 0n25 % milk powder, the filters were probed with 10' c.p.m.\ml nick-translated JCV NF-1 oligonucleotide concatemer in binding buffer containing 0n25 % milk powder and 10 µg\ml sonicated salmon sperm DNA. After 3 h hybridization at 4 mC, the filters were washed three times for 15 min each with binding buffer containing 0n25 % milk powder. Finally, the filters were wrapped in Saran Wrap and exposed to X-ray film overnight at k70 mC. Positive plaques were identified and re-screened until they were homogeneously positive.
Sequence analysis. The cDNA, which was cloned into pBluescript KS(j) (Stratagene), was sequenced by using a kit from United States Biochemical according to the manufacturer's instructions. The sequence was compared with known sequences in GenBank by BLAST search.
Northern blot analysis. Total RNA from undifferentiated (UD), RA-and DMSO-differentiated EC cells, U87 MG and HeLa cells was extracted by using a kit from Promega, according to the manufacturer's instructions. Twenty µg total RNA was electrophoresed on a 1 % formaldehyde-agarose gel and transferred to nylon membrane (Gilman Sciences). The filter was blocked with Denhardt's solution and probed with 10' c.p.m.\ml nick-translated kNF-1 cDNA overnight at 60 mC. After hybridization, the filter was washed and exposed to X-ray film. The hybridized probe was stripped with 0n1iSSC and 0n1 % SDS and reprobed with an actin probe as described above.
Gel-shift analysis. The sequences of JCV NF-1 oligonucleotides were described by Kumar et al. (1993) . The probes were prepared by endlabelling the oligonucleotides in the presence of [α-$#P]dCTP. The binding reactions were done in a volume of 35 µl in buffer containing 10 mM Tris-HCl, pH 7n8 ; 1 mM EDTA ; 5 mM DTT ; 150 mM KCl ; 12 % glycerol ; 10 µg poly(dI.dC), 10 ng labelled probe and 4 µl in vitrotranslated BAG-1. The reaction mixture was incubated at room temperature for 30 min. The reaction products were resolved on a 4 % non-denaturing PAGE gel. Gels were then dried and subjected to autoradiography.
Southwestern blot analysis. Nuclear extracts from UD, RA-and DMSO-differentiated EC cells, HeLa and U87 MG cells were resolved on a 10 % SDS-PAGE gel and transferred to PVDF membrane in a semi-dry transfer apparatus (Bio-Rad) according to the manufacturer's instructions. The filters were then blocked overnight at 4 mC with 5 % milk powder in a binding buffer containing 25 mM HEPES-NaOH, pH 7n9; 5 mM MgCl # ; 0n5 mM DTT and 25 mM NaCl. After blocking, the filters were probed with 10' c.p.m.\ml nick-translated JCV NF-1 oligonucleotide in binding buffer. The filters were then washed with binding buffer without milk powder, dried and subjected to autoradiography.
CAT assays. CAT assays were performed as described previously (Nakshatri et al., 1990) . The percentage of acetylation was quantified by liquid scintillation and normalized on the basis of β-galactosidase activity.
Results

Isolation of a cDNA encoding a JCV NF-1 regionbinding protein from P19 RA-differentiated cells
Previous studies from our laboratory indicated that NF-1 sites present in the JCV enhancer play an important role in the neuron-specific expression of JCV (Nakshatri et al., 1990 ; Kumar et al., 1993) . Furthermore, a novel protein seems to interact with the NF-1 motif (Kumar, 1994) . This protein is present in both neuronal and non-neuronal cells and is able to interact specifically and directly with the JCV NF-1 motif. To examine the identity of this protein, an NF-1 oligonucleotide probe was used to screen a λgt22A cDNA expression library from RA-differentiated EC cells. After screening more than 2i10& plaques, two positive plaques were identified. The specificity of interaction of these plaques with the NF-1 probe was further confirmed. Replica filter papers containing plaques of the two positive recombinant phages were hybridized with : (i) WT NF-1 ; (ii) mt NF-1 (Kumar et al., 1993) and (iii) a nonspecific oligonucleotide. Only the WT NF-1 probe (data not shown), and not the mutant or non-specific probes, interacted with the positive recombinant plaques (data not shown).
Analysis of DNA extracted from the two positive plaques yielded the same sequence, and only one plaque was characterized further. The positive recombinant phage encoding the JCV NF-1 region-binding protein was termed kNF-1 (Kumar, 1994) . Analysis of kNF-1 revealed a " 1 kb DNA fragment (Fig. 1 a) with perfect sequence identity to BAG-1 (Fig. 1 b ; Takayama et al., 1995) . The kNF-1 cDNA contains an open reading frame (ORF) of 229 amino acids with the potential to encode a 30 kDa protein. The ORF corresponds to sequences spanning the entire BAG-1 sequence. BAG-1 is a Bcl-2-interacting protein isolated from a mouse embryonic cDNA library in the yeast two-hybrid system (Takayama et al., 1995) . The sequence identity of kNF-1 to BAG-1 is likely to reflect the isolation of the same gene.
Northern blot analysis
JCV expresses its genes and replicates efficiently in brain cells (Kenney et al., 1984) and the NF-1 sites in the JCV regulatory region were shown to be critical for neuron-specific expression (Kumar et al., 1993) . To determine the cell-specific expression of kNF-1, Northern blot analysis was performed with RNAs derived from UD, RA-and DMSO-differentiated EC cells, U87 MG and HeLa cells. Probing and washing were performed under high-stringency conditions to eliminate crosshybridization. As shown in Fig. 2 (a) , a major " 1n5 kb RNA species was detected in UD, RA-and DMSO-differentiated EC 2) or in all the three NF-1 sites (DM 10 CAT) (lanes 3 and 4) (Kumar et al., 1993) was co-transfected with (lanes 2 and 4) or without (lanes 1 and 3) 10 µg kNF-1. Cell extracts were prepared 48 h post-transfection and CAT activity was measured. The graph below shows the adjusted percentage acetylation values.
cells, whereas a " 1n7 kb RNA species was detected in HeLa cells. From the intensity of the bands, it appears that kNF-1 RNA was present at approximately similar levels in all cell types with the exception of U87 MG cells, which did not express kNF-1 RNA. Stripping and reprobing the same blot with an actin probe showed that equal amounts of RNA were loaded on the gel (Fig. 2 b) . These observations indicate that a major 1n5 kb kNF-1 RNA species is produced in neuron-like cells.
Nucleoprotein complex formation
The binding activities of crude nuclear extracts and in vitrotranslated kNF-1 were tested by Southwestern and gel-shift analyses, respectively. To examine the ability of in vitrotranslated kNF-1 protein to bind the JCV NF-1 oligonucleotide, a gel-shift assay was performed. As shown in Fig. 3 (a) , in vitrotranslated kNF-1 protein reduced the mobility of the JCV NF-1 probe (lane 2). This retardation was eliminated by the addition of a 200-fold excess of unlabelled WT JCV NF-1 oligonucleotide (lane 3), but not by the addition of the mutant JCV NF-1 oligonucleotide (lane 4), confirming the specificity of binding of kNF-1 protein to the JCV NF-1 oligonucleotide. No retardation was observed with a reticulocyte lysate (lanes 5-7) or with in vitro-translated luciferase protein (lanes 8-10) .
The DNA-binding activity of kNF-1 was further confirmed in Southwestern (DNA-protein) blot assays. Nuclear extracts from the cell types indicated were resolved on an SDS-PAGE gel, transferred to PVDF membrane and probed with WT JCV NF-1 oligonucleotide. A 30 kDa protein was detected in P19 RA, P19 DMSO and HeLa cell extracts (Fig. 3 b) . The fastermigrating protein in P19 RA cells may be a proteolytically degraded kNF-1 (Devireddy, 1995) . However, a 30 kDa protein was not detected in extracts from U87 MG glioblastoma cells. Furthermore, these cells are negative for kNF-1 mRNA expression (Fig. 2) . A 30 kDa protein was also detected in extracts from P19 RA, P19 DMSO and HeLa cells in Western blot assays using a BAG-1-specific antibody (data not shown). The identity and nature of the 97 kDa protein present in all cell types are not known. However, a similar-sized protein present in glial and non-glial cells was also shown to interact with the JCV B domain (which harbours the NF-1 site) (Khalili et al., 1988) . In summary, these results suggest that BAG-1 binds the JCV NF-1 oligonucleotide.
Transcriptional activity of kNF-1 cDNA in HeLa cells
To examine the transcriptional activity of the kNF-1 protein, the kNF-1 cDNA was cloned into a eukaryotic expression vector, pRc\CMV. Non-neuronal HeLa cells that do not support JCV transcription were employed (Tada et al., 1989) . Reporter plasmids with the CAT gene under the control of the JCV early (JCV E ) or late (JCV L ) promoters were transfected into HeLa cells alone or with pCMV-kNF-1. A basal level of activity from the JCV E and JCV L promoters was detected in HeLa cells (Fig. 4 a) . Co-transfection of kNF-1 cDNA resulted in 6-fold and 5-fold activation of the JCV E and JCV L promoters, respectively (Fig. 4 a) . Co-transfection of pRc\CMV alone had no effect (data not shown). The RII E expression plasmid, containing only one JCV 98 bp repeat, was also transactivated, by 2n5-fold (Fig. 4 a) . The BK virus early promoter was not transactivated by kNF-1 cDNA (Fig.  4 a) . A JCV enhancer\promoter containing mutations in the NF-1 sites was not transactivated by kNF-1, suggesting that the integrity of these sites is necessary for kNF-1-mediated transactivation (Fig. 4 b) . In summary, these results suggest that kNF-1 specifically transactivated JCV promoters.
Discussion
In this study, we isolated a cDNA (kNF-1) encoding a JCV NF-1 motif-binding protein from P19 RA-differentiated cells that is identical to a Bcl-2-interacting protein, BAG-1 (Fig. 1) . Furthermore, the kNF-1 protein bound specifically to the JCV NF-1 region and up-regulated transcription of the viral promoters in non-glial cells (Figs 3 and 4) . Northern blot analysis for detection of kNF-1 mRNA revealed the presence of BAG-1 mRNA of varying sizes (Fig. 2) .
JCV infection occurs during childhood in the majority of the population, but only during immunosuppression does this virus become pathogenic and cause PML. The virus replicates only in neuronal cells, but the mechanism that determines neuron-specific expression of virus genes is not completely understood. It has been postulated that a regulatory pathway that includes participation of neuronal and non-neuronal transcription factors plays a role in the neuron-specific regulation of JCV (reviewed in Raj & Khalili, 1995) . The functional redundancy of promoter elements and the requirement for multiple cellular transcription factors further support the hypothesis of multiple cis and trans determinants of JCV neurotropism.
The data presented here led to the identification of a novel transcription factor, BAG-1, that bound specifically to the JCV NF-1 sequences and up-regulated transcription of the JCV early and late promoters. Recent studies indicate that BAG-1 and its longer isoforms BAG-1M and BAG-1L influence a wide variety of cellular phenotypes through their interaction with Hsc70\Hsp70, including resistance to apoptosis, promotion of cell proliferation, enhancement of tumour cell migration and alteration of transcriptional activity of steroid-hormone receptors (Takayama et al., 1995 ; Wang et al., 1996 ; Bardelli et al., 1996 ; Liu et al., 1998 ; . The ability of the BAG-1 family of proteins to modulate the chaperone activity of Hsc70\Hsp70 may have different consequences for the various proteins whose functions are controlled by conformational change. For example, BAG-1 proteins have been reported to bind Bcl-2, Raf-1, androgen receptor and PDGF receptor and enhance their function. Conversely, interaction of BAG-1 with retinoic acid receptor, glucocorticoid receptor and Siah-1 seems to inhibit their activity (Takayama et al., 1995 ; Wang et al., 1996 ; Bardelli et al., 1996 ; Liu et al., 1998 ; Kullmann et al., 1998 ; Matsuzawa et al., 1998 ; . The Bcl-2 protein, which has an anti-apoptotic function, recruits cytosolic proteins to internal membranes, including Raf-1 and BAG-1 (Wang et al., 1996 ; Takayama et al., 1998) . Bcl-2 also negatively regulates p53 transcriptional activity (Froesch et al., 1999) , possibly by sequestering transcription factors necessary for p53 transcriptional activity. Analogously, BAG-1 may modulate JCV expression by interacting with transcription factors.
It is intriguing that a ubiquitously expressed, anti-apoptotic and chaperone regulator BAG-1 activates the expression of JCV. Many distinct promoter elements, including NF-1, contribute to the tropism of the JCV promoter (Nakshatri et al., 1990 ; Kumar et al., 1993) . The restriction in expression of individual transcription factors to glial cells, including Tst-1, NF-1 and Sp1, may confer neuron-specific expression to JCV (Nakshatri et al., 1990 ; Henson et al., 1992 ; Wegner et al., 1993) . Therefore, the relative abundance of transcription factors, rather than a single determining factor, may account for the neurotropism of JCV.
